REGN - Spark Newswire

1 minute read

U.S. FDA Accepts Regeneron’s Diabetic Retinopathy Candidate Submission For Review

Today, 8:41 PM

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

REGN

1 minute read

Intellia’s Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

By Vandana Singh

Today, 8:41 PM

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome…

NTLA

2 minute read

Regeneron Pharmaceuticals Whale Trades Spotted

By Benzinga Insights

Today, 8:41 PM

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 34 strange trades.

REGN

1 minute read

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today

By Benzinga Insights

Today, 8:41 PM

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.08%. Currently, Regeneron Pharmaceuticals has a market capitalization of $61.64 billion.

REGN

3 minute read

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax’s COVID-19 Shot, New Data On Moderna’s Omicron Vaccine, DBV Tech’s Encouraging Peanut Allergy Trial Data

By Vandana Singh

Today, 8:41 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

APLS

1 minute read

U.S. FDA Approves Regeneron And Sanofi’s Lead Drug For Skin Inflammation In Children

By Ragothaman Srinivasan

Today, 8:41 PM

The U.S.

REGN

17 minute read

FDA
News

Regeneron Says FDA Approves Dupixent (dupilumab) As First Biologic Medicine For Children Aged 6 Months To 5 Years With Moderate-To-Severe Atopic Dermatitis

By Benzinga Newsdesk

Today, 8:41 PM

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Children treated with Dupixent and topical corticosteroids (TCS) achieved

REGN

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 6, 2022

By Benzinga Insights

Today, 8:41 PM

Upgrades

ACB

1 minute read

Jefferies Initiates Coverage On Regeneron Pharmaceuticals with Underperform Rating, Announces Price Target of $536

By Benzinga Newsdesk

Today, 8:41 PM

Jefferies analyst Akash Tewari initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform rating and announces Price Target of $536.

REGN

3 minute read

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

By Shanthi Rexaline

Today, 8:41 PM

Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.

ACER

Feed Symbols: REGN